Grandeur Peak Global Advisors LLC Decreases Stock Holdings in Charles River Laboratories International, Inc. (NYSE:CRL)

Grandeur Peak Global Advisors LLC lessened its stake in Charles River Laboratories International, Inc. (NYSE:CRL - Free Report) by 40.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 30,055 shares of the medical research company's stock after selling 20,488 shares during the period. Grandeur Peak Global Advisors LLC owned 0.06% of Charles River Laboratories International worth $5,548,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other large investors have also added to or reduced their stakes in CRL. Versant Capital Management Inc increased its stake in Charles River Laboratories International by 1,071.4% during the 4th quarter. Versant Capital Management Inc now owns 164 shares of the medical research company's stock valued at $30,000 after purchasing an additional 150 shares in the last quarter. Pinnacle Bancorp Inc. increased its position in shares of Charles River Laboratories International by 52.0% in the 4th quarter. Pinnacle Bancorp Inc. now owns 190 shares of the medical research company's stock valued at $35,000 after acquiring an additional 65 shares during the period. Pilgrim Partners Asia Pte Ltd purchased a new position in Charles River Laboratories International in the 4th quarter worth $48,000. Tortoise Investment Management LLC lifted its position in Charles River Laboratories International by 77.7% during the 4th quarter. Tortoise Investment Management LLC now owns 263 shares of the medical research company's stock worth $49,000 after acquiring an additional 115 shares during the period. Finally, Huntington National Bank increased its holdings in shares of Charles River Laboratories International by 120.6% in the fourth quarter. Huntington National Bank now owns 300 shares of the medical research company's stock valued at $55,000 after purchasing an additional 164 shares during the period. 98.91% of the stock is currently owned by institutional investors.

Insider Buying and Selling at Charles River Laboratories International

In other news, CEO James C. Foster acquired 6,075 shares of the stock in a transaction that occurred on Thursday, February 20th. The shares were purchased at an average cost of $165.01 per share, for a total transaction of $1,002,435.75. Following the transaction, the chief executive officer now directly owns 183,639 shares in the company, valued at approximately $30,302,271.39. This represents a 3.42 % increase in their position. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Joseph W. Laplume sold 4,400 shares of the company's stock in a transaction on Thursday, February 20th. The stock was sold at an average price of $162.50, for a total transaction of $715,000.00. Following the transaction, the executive vice president now owns 20,013 shares of the company's stock, valued at approximately $3,252,112.50. The trade was a 18.02 % decrease in their position. The disclosure for this sale can be found here. 1.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of analysts have recently weighed in on CRL shares. Robert W. Baird cut their price objective on shares of Charles River Laboratories International from $177.00 to $173.00 and set a "neutral" rating on the stock in a research note on Thursday, February 20th. Morgan Stanley cut their price target on Charles River Laboratories International from $220.00 to $184.00 and set an "equal weight" rating on the stock in a research report on Wednesday, February 5th. Redburn Atlantic raised Charles River Laboratories International from a "sell" rating to a "neutral" rating and set a $188.00 price objective for the company in a report on Monday, March 3rd. UBS Group reaffirmed a "neutral" rating and set a $185.00 target price (down from $250.00) on shares of Charles River Laboratories International in a report on Friday, January 17th. Finally, Barclays decreased their price target on Charles River Laboratories International from $160.00 to $145.00 and set an "equal weight" rating for the company in a report on Thursday, April 10th. One equities research analyst has rated the stock with a sell rating and sixteen have given a hold rating to the company's stock. According to MarketBeat, Charles River Laboratories International presently has an average rating of "Hold" and an average target price of $182.00.

Charles River Laboratories International Stock Up 0.8 %

Shares of Charles River Laboratories International stock traded up $0.86 during trading on Thursday, hitting $105.11. 693,639 shares of the stock were exchanged, compared to its average volume of 886,146. The stock has a market cap of $5.16 billion, a price-to-earnings ratio of 700.47, a price-to-earnings-growth ratio of 4.54 and a beta of 1.45. The company has a debt-to-equity ratio of 0.65, a current ratio of 1.41 and a quick ratio of 1.14. The firm's 50-day moving average price is $153.13 and its 200 day moving average price is $175.23. Charles River Laboratories International, Inc. has a 12-month low of $91.86 and a 12-month high of $254.15.

Charles River Laboratories International (NYSE:CRL - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The medical research company reported $2.66 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $2.50 by $0.16. Charles River Laboratories International had a return on equity of 14.69% and a net margin of 0.52%. The firm had revenue of $1 billion during the quarter, compared to the consensus estimate of $983.63 million. During the same period in the prior year, the company posted $2.46 earnings per share. The firm's quarterly revenue was down 1.1% compared to the same quarter last year. As a group, analysts forecast that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

Charles River Laboratories International Profile

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).